ity during TCZ treatment (3) .
They also reported that TCZ decreased the serum level of matrix metalloproteinase-3 (MMP-3), as well as CRP and ferritin. However, MMP-3 is not a disease activity marker for AOSD. The decrease of serum MMP-3 was not a direct effect of TCZ, but rather it was due to the reduction of the prednisolone dose. Glucocorticoids increase the serum level of MMP-3, although the mechanism involved is unclear. In fact, the MMP-3 level is increased in any disease by highdose glucocorticoid therapy (5).
Yoshida et al suggested that drugs targeting IL-18 may be beneficial for the treatment of AOSD. Whether IL-18 is a treatment target for AOSD or merely an indicator of disease activity needs to be elucidated in the future.
